Sermo offers instant focus groups

Share this article:
Sermo is offering clients on-demand physician focus groups.

The physician online community, which claims 111,000 MDs, is launching Sermo Panels, a service aimed at ad agencies, PR shops and market research firms as well as its pharma industry clients.

“We're faster than anyone out there now, and they're getting deep feedback from our physicians,” said Greg Shenk, marketing director at Sermo. “You don't have to worry about travel or logistics, and it's an asynchronous discussion, so you don't have to have doctors here from 2-5 pm.

Participating physicians commit to putting a set amount of time into the discussion — usually 90 minutes over three to five days, said Shenk — and get an honoraria, typically $150 to $300 per panel. Sermo doesn't take a cut of that, instead charging a lump sum, typically around $16,000 per full panel, or $10,000 for the no-frills “express” version. That offering, aimed at smaller clients and cash-strapped agencies, leaves the analysis to the client.

Sermo said the service is ideal for marketing intelligence, advisory boards, medical affairs support or utilization research.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...